尊龙凯时
About us
尊龙凯时:Our Values
尊龙凯时:Development Milestone
Products
尊龙凯时:Product List for API
尊龙凯时:Recommended API
尊龙凯时:Product list for Chemicals and Intermediates
Product list for Chemicals and Intermediates
News
尊龙凯时:Contract Manufacturing
尊龙凯时:API and Pharmaceutical Intermediates
尊龙凯时:OTC and Generics
尊龙凯时:Investor Relation
尊龙凯时:PERIODIC REPORT
尊龙凯时:INTERIM REPORT
尊龙凯时:INVESTORS SERVICE
尊龙凯时:Contact Us
About us
News
尊龙凯时:Investor Relation
Products
尊龙凯时:Contract Manufacturing
尊龙凯时:Contact Us
Investor Relation
Investor Relation
PERIODIC REPORT
尊龙凯时:INTERIM REPORT
尊龙凯时:INVESTORS SERVICE
Overseas Regulatory Announcement-Announcement in Connection with the Drugs of a Wholly-owned Subsidiary Passing the Generic Drugs Consistency Evaluation
2024-12-03
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024
2024-12-02
Overseas Regulatory Announcement-Announcement on Having Obtained the Notification of Approval of Supplementary Drug Application and Other Relevant Information
2024-12-02
Overseas Regulatory Announcement-Announcement on Having Obtained the Notification of Approval of Supplementary Drug Application and Other Relevant Information
2024-12-02
Overseas Regulatory Announcement -Announcement of Obtaining FDA Registration Approval Letter for Sevelamer Carbonate (Active Pharmaceutical Ingredients)(1)
2024-11-25
Reply Slip for the Second Extraordinary General Meeting for the Year 2024
2024-11-13
Proxy Form for the Second Extraordinary General Meeting for the Year 2024
2024-11-13
Notice of Extraordinary General Meeting
2024-11-13
(1) Continuing Connected Transactions; And(2) Notice of Extraordinary General Meeting
2024-11-13
Overseas Regulatory Announcement-Announcement on Febuxostat Tablets Having Obtained the Drug Registration Certificate
2024-11-11
<
1
2
3
4
5
6
7
...
>